IMGN News and Press, ImmunoGen Inc. From 08/02/19

ImmunoGen (NASDAQ: IMGN ): Q2 GAAP EPS of -$0.29 beats by $0.04 . More news on: ImmunoGen, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Registration Study for Mirvetuximab Soravtansine in Ovarian Cancer on Track to Start by Year-End Full Data from the Phase 3 FORWARD I Trial and Initial FORWARD II Triplet Data to be Presented at ESMO Recommended Phase 2 Dose and Schedule for IMGN632 Determined; Combination and MR...

ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, August 2, 2019 to discuss its second quarter operating results. Management...

If you begin with a prayer, you can think more clearly and make fewer mistakes. - Sir John Templeton I've always enjoyed a comeback story, be it Rocky Balboa or a "beaten down but not out" stock. In bioscience investment, when a depressed stock makes a successful comeback, the profits ar...

XpresSpa Group (NASDAQ: XSPA ) -53% . More news on: XpresSpa Group, Inc., Aclaris Therapeutics, Inc., Pier 1 Imports, Inc., Stocks on the move, Read more ...

Aimed at extending is cash runway while it conducts another Phase 3 trial for antibody-drug conjugate (ADC) mirvetuximab soravtansine, ImmunoGen (NASDAQ: IMGN ) will restructure its business, including the termination of 220 employees. More news on: ImmunoGen, Inc., Healthcare stock...

Company Will Prioritize Continued Development of Mirvetuximab Soravtansine and a Select Portfolio of Earlier-Stage Candidates Cash Runway Extended Through Readout of Mirvetuximab Soravtansine Pivotal Trial in Ovarian Cancer Conference Call to be Held at 8 a.m. ET Today Immun...

SPDR Biotech ETF (NYSE: XBI ) provides investors diversified exposure to one of the most exciting industries in the market. Diversified is a relative term here because biotechnology companies, particularly those that are still in early stages of drug development, are often times the riskie...

People who succeed in the stock market also accept periodic losses, setbacks, and unexpected occurrences. Calamitous drops do not scare them out of the game. - Peter Lynch As the bioscience sector is inherently volatile, some investors can be deterred by the excessive swing in the share pr...

Results to be Presented at 2019 ASCO Annual Meeting Combination Demonstrates Significant Anti-Tumor Activity and Favorable Safety and Tolerability in Platinum-Resistant Disease Findings Support Ongoing Studies of Doublet Combination in Platinum-Agnostic Disease and Triplet in Plat...